Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phase 3 Trial Testing Eftilagimod Alpha (Soluble LAG-3) in HER2-neg/Low Metastatic Breast Cancer Patients Receiving Paclitaxel, Following an Open-label Dose Optimization

NCT05747794 is registered in ClinicalTrials.gov with Immutep S.A.S. as lead sponsor.

NCT NCT05747794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05747794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phase 3 Trial Testing Eftilagimod Alpha (Soluble LAG-3) in HER2-neg/Low Metastatic Breast Cancer Patients Receiving Paclitaxel, Following an Open-label Dose Optimization
Lead sponsor
Immutep S.A.S.
Phase
Phase 2/3
Overall status
Terminated
Start date
May 22, 2023
Completion date
June 30, 2026
Enrollment
72 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma